New insights into the immunopathogenesis of systemic lupus erythematosus

Nature Reviews Rheumatology

Volumn 12, Issue 12, 2016, Pages 716-730

  Tsokos, George C ^a   Lo, Mindy S ^b   Reis, Patricia Costa ^c   Sullivan, Kathleen E ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF LISBON   (Portugal)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; INTERFERON; MICRORNA; NUCLEIC ACID; ANTIGEN ANTIBODY COMPLEX; TOLL LIKE RECEPTOR;

ANTIBODY PRODUCTION; APOPTOSIS; B LYMPHOCYTE; BONE MARROW CELL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CLINICAL RESEARCH; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE MODEL; ENVIRONMENTAL FACTOR; EPIGENETICS; EXTRACELLULAR TRAP; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC SUSCEPTIBILITY; GENETIC VARIATION; HERITABILITY; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE; MOLECULARLY TARGETED THERAPY; MOUSE MODEL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TISSUE INJURY; ANIMAL; ANTIGEN ANTIBODY COMPLEX; BRAIN VASCULITIS; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOUSE; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; APOPTOSIS; AUTOANTIBODIES; B-LYMPHOCYTES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; EXTRACELLULAR TRAPS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; INTERFERONS; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; LYMPHOCYTES; MICE; MICRORNAS; MYELOID CELLS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS;

EID: 84996604183     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2016.186     Document Type: Review

References (236)

1. Bernatsky S., et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 54, 2550-2557 (2006
2. Zhu T. Y., Tam L. S., & Li E. K. Cost of illness studies in systemic lupus erythematosus: a systematic review. Arthritis Care Res. (Hoboken) 63, 751-760 (2011
3. Casciola-Rosen L. A., Anhalt G., & Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J. Exp. Med. 179, 1317-1330 (1994
4. Theofilopoulos A. N., Kono D. H., Beutler B., & Baccala R. Intracellular nucleic acid sensors and autoimmunity. J. Interferon Cytokine Res. 31, 867-886 (2011
5. Dieker J., et al. Circulating apoptotic microparticles in systemic lupus erythematosus patients drive the activation of dendritic cell subsets and prime neutrophils for NETosis. Arthritis Rheumatol. 68, 462-472 (2016
6. Leadbetter E. A., et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416, 603-607 (2002
7. Achtman J. C., & Werth V. P. Pathophysiology of cutaneous lupus erythematosus. Arthritis Res. Ther. 17, 182 (2015
8. Grimaldi C. M. Sex and systemic lupus erythematosus: the role of the sex hormones estrogen and prolactin on the regulation of autoreactive B cells. Curr. Opin. Rheumatol. 18, 456-461 (2006
9. Shelly S., Boaz M., & Orbach H. Prolactin and autoimmunity. Autoimmun. Rev. 11, A465-A470 2012
10. Cunningham M., & Gilkeson G. Estrogen receptors in immunity and autoimmunity. Clin. Rev. Allergy Immunol. 40, 66-73 (2011
11. Dorgham K., et al. Ultraviolet light converts propranolol a nonselective β blocker and potential lupus-inducing drug into a proinflammatory AhR ligand. Eur. J. Immunol. 45, 3174-3187 (2015
12. Nelson P., Rylance P., Roden D., Trela M., & Tugnet N. Viruses as potential pathogenic agents in systemic lupus erythematosus. Lupus 23, 596-605 (2014
13. Sawalha A. H., Schmid W. R., Binder S. R., Bacino D. K., & Harley J. B. Association between systemic lupus erythematosus and Helicobacter pylori seronegativity. J. Rheumatol. 31, 1546-1550 (2004
14. Ram M., et al. The putative protective role of hepatitis B virus (HBV) infection from autoimmune disorders. Autoimmun. Rev. 7, 621-625 (2008
15. Chen M., et al. Toxoplasma gondii infection inhibits the development of lupus-like syndrome in autoimmune (New Zealand Black × New Zealand White) F1 mice. Int. Immunol. 16, 937-946 (2004
16. Gan L., et al. Gene expression profiles from disease discordant twins suggest shared antiviral pathways and viral exposures among multiple systemic autoimmune diseases. PLoS ONE 10, e0142486 2015
17. Shi L., et al. The SLE transcriptome exhibits evidence of chronic endotoxin exposure and has widespread dysregulation of non-coding and coding RNAs. PLoS ONE 9, e93846 2014
18. Nockher W. A., Wigand R., Schoeppe W., & Scherberich J. E. Elevated levels of soluble CD14 in serum of patients with systemic lupus erythematosus. Clin. Exp. Immunol. 96, 15-19 (1994
19. Zhai J. X., et al. PDTC attenuate LPS-induced kidney injury in systemic lupus erythematosus-prone MRL/lpr mice. Mol. Biol. Rep. 39, 6763-6771 (2012
20. Pasare C., & Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Microbes Infect. 6, 1382-1387 (2004
21. Gallo P. M., et al. Amyloid-DNA composites of bacterial biofilms stimulate autoimmunity. Immunity 42, 1171-1184 (2015
22. Belkaid Y., & Hand T. W. Role of the microbiota in immunity and inflammation. Cell 157, 121-141 (2014
23. Hevia A., et al. Intestinal dysbiosis associated with systemic lupus erythematosus. mBio 5, e01548-e01514 2014
24. Johnson B. M., Gaudreau M. C., Al Gadban M. M., Gudi R., & Vasu C. Impact of dietary deviation on disease progression and gut microbiome composition in lupus-prone SNF1 mice. Clin. Exp. Immunol. 181, 323-337 (2015
25. Zhang H., Liao X., Sparks J. B., & Luo X. M. Dynamics of gut microbiota in autoimmune lupus. Appl. Environ. Microbiol. 80, 7551-7560 (2014
26. Furusawa Y., et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504, 446-450 (2013
27. Arpaia N., et al. Metabolites produced by commensal bacteria promote peripheral regulatory T cell generation. Nature 504, 451-455 (2013
28. Van Praet J. T., et al. Commensal microbiota influence systemic autoimmune responses. EMBO J. 34, 466-474 (2015
29. Alarcon-Segovia D., et al. Familial aggregation of systemic lupus erythematosus rheumatoid arthritis and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis Rheum. 52, 1138-1147 (2005
30. Morris D. L., et al. Unraveling multiple MHC gene associations with systemic lupus erythematosus: model choice indicates a role for HLA alleles and non-HLA genes in Europeans. Am. J. Hum. Genet. 91, 778-793 (2012
31. Cui Y., Sheng Y., & Zhang X. Genetic susceptibility to SLE: recent progress from GWAS. J. Autoimmun. 41, 25-33 (2013
32. Farh K. K., et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518, 337-343 (2015
33. Martin P., et al. Capture Hi C reveals novel candidate genes and complex long-range interactions with related autoimmune risk loci. Nat. Commun. 6, 10069 (2015
34. Li Y. R., et al. Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases. Nat. Med. 21, 1018-1027 (2015
35. Harley I. T., Kaufman K. M., Langefeld C. D., Harley J. B., & Kelly J. A. Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies. Nat. Rev. Genet. 10, 285-290 (2009
36. Belot A., & Cimaz R. Monogenic forms of systemic lupus erythematosus: new insights into SLE pathogenesis. Pediatr. Rheumatol. Online J. 10, 21 (2012
37. Richardson B., et al. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 33, 1665-1673 (1990
38. Richardson B., Ray D., & Yung R. Murine models of lupus induced by hypomethylated T cells. Methods Mol. Med. 102, 285-294 (2004
39. Sawalha A. H., et al. Defective T cell ERK signaling induces interferon-regulated gene expression and overexpression of methylation-sensitive genes similar to lupus patients. Genes Immun. 9, 368-378 (2008
40. Coit P., et al. Renal involvement in lupus is characterized by unique DNA methylation changes in naive CD4+ T cells. J. Autoimmun. 61, 29-35 (2015
41. Coit P., et al. Epigenetic reprogramming in naive CD4+ T cells favoring T cell activation and non-TH1 effector T cell immune response as an early event in lupus flares. Arthritis Rheumatol. 68, 2200-2209 (2016
42. Lim U., & Song M. A. Dietary and lifestyle factors of DNA methylation. Methods Mol. Biol. 863, 359-376 (2012
43. Cooney C. A., Dave A. A., & Wolff G. L. Maternal methyl supplements in mice affect epigenetic variation and DNA methylation of offspring. J. Nutr. 132, 2393S-2400S (2002
44. Zhao M., et al. Increased 5 hydroxymethylcytosine in CD4+ T cells in systemic lupus erythematosus. J. Autoimmun. 69, 64-73 (2016
45. Mishra N., Reilly C. M., Brown D. R., Ruiz P., & Gilkeson G. S. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J. Clin. Invest. 111, 539-552 (2003
46. Regna N. L., et al. HDAC expression and activity is upregulated in diseased lupus-prone mice. Int. Immunopharmacol. 29, 494-503 (2015
47. Regna N. L., et al. Specific HDAC6 inhibition by ACY 738 reduces SLE pathogenesis in NZB/W mice. Clin. Immunol. 162, 58-73 (2016
48. Skov S., et al. Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression. Blood 101, 1430-1438 (2003
49. Yang Y., et al. The effect of mycophenolic acid on epigenetic modifications in lupus CD4+ T cells. Clin. Immunol. 158, 67-76 (2015
50. Zhang Z., Song L., Maurer K., Petri M. A., & Sullivan K. E. Global H4 acetylation analysis by ChIP-chip in systemic lupus erythematosus monocytes. Genes Immun. 11, 124-133 (2010
51. Coit P., et al. Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naive CD4+ T cells from lupus patients. J. Autoimmun. 43, 78-84 (2013
52. Zhang Z., et al. Interferon regulatory factor 1 marks activated genes and can induce target gene expression in systemic lupus erythematosus. Arthritis Rheumatol. 67, 785-796 (2015
53. Shi L., et al. Monocyte enhancers are highly altered in systemic lupus erythematosus. Epigenomics 7, 921-935 (2015
54. Zhang Z., Song L., Maurer K., Bagashev A., & Sullivan K. E. Monocyte polarization: the relationship of genome-wide changes in H4 acetylation with polarization. Genes Immun. 12, 445-456 (2011
55. Zhang Z., Maurer K., Perin J. C., Song L., & Sullivan K. E. Cytokine-induced monocyte characteristics in SLE. J. Biomed. Biotechnol. 2010, 507475 (2010
56. Kanno T., et al. BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones. Nat. Struct. Mol. Biol. 21, 1047-1057 (2014
57. Wei S., Sun Y., & Sha H. Therapeutic targeting of BET protein BRD4 delays murine lupus. Int. Immunopharmacol. 29, 314-319 (2015
58. Wu L., & Belasco J. G. Let me count the ways: mechanisms of gene regulation by miRNAs and siRNAs. Mol. Cell 29, 1-7 (2008
59. Dai Y., et al. Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus 16, 939-946 (2007
60. Dai Y., et al. Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol. Int. 29, 749-754 (2009
61. Costa-Reis P., et al. The role of microRNAs and human epidermal growth factor receptor 2 in proliferative lupus nephritis. Arthritis Rheumatol. 67, 2415-2426 (2015
62. Carlsen A. L., et al. Circulating microRNA expression profiles associated with systemic lupus erythematosus. Arthritis Rheum. 65, 1324-1334 (2013
63. Yan S., Yim L. Y., Lu L., Lau C. S., & Chan V. S. MicroRNA regulation in systemic lupus erythematosus pathogenesis. Immune Netw. 14, 138-148 (2014
64. Liu Y., et al. MicroRNA 30a promotes B cell hyperactivity in patients with systemic lupus erythematosus by direct interaction with Lyn. Arthritis Rheum. 65, 1603-1611 (2013
65. Pan W., et al. MicroRNA 21 and microRNA 148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J. Immunol. 184, 6773-6781 (2010
66. Xiao C., et al. Lymphoproliferative disease and autoimmunity in mice with increased miR 17 92 expression in lymphocytes. Nat. Immunol. 9, 405-414 (2008
67. Kang S. G., et al. MicroRNAs of the miR 17 approximately 92 family are critical regulators of TFH differentiation. Nat. Immunol. 14, 849-857 (2013
68. Thai T. H., et al. Deletion of microRNA 155 reduces autoantibody responses and alleviates lupus-like disease in the Faslpr mouse. Proc. Natl Acad. Sci. USA 110, 20194-20199 (2013
69. Stagakis E., et al. Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR 21 regulates aberrant T cell responses through regulation of PDCD4 expression. Ann. Rheum. Dis. 70, 1496-1506 (2011
70. Hennessy E. J., & Moore K. J. Using microRNA as an alternative treatment for hyperlipidemia and cardiovascular disease: cardio-miRs in the pipeline. J. Cardiovasc. Pharmacol. 62, 247-254 (2013
71. Bennett L., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197, 711-723 (2003
72. Baechler E. C., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl Acad. Sci. USA 100, 2610-2615 (2003
73. Kirou K. A., et al. Coordinate overexpression of interferon-α induced genes in systemic lupus erythematosus. Arthritis Rheum. 50, 3958-3967 (2004
74. Sharma S., et al. Widely divergent transcriptional patterns between SLE patients of different ancestral backgrounds in sorted immune cell populations. J. Autoimmun. 60, 51-58 (2015
75. Juang Y T., et al. A systemic lupus erythematosus gene expression array in disease diagnosis and classification: a preliminary report. Lupus 20 243-249 2011
76. Grammatikos A. P., et al. A T cell gene expression panel for the diagnosis and monitoring of disease activity in patients with systemic lupus erythematosus. Clin. Immunol. 150, 192-200 (2014
77. Bradley S J., Suarez-Fueyo A., Moss D. R., Kyttaris V. C., & Tsokos G. C. T cell transcriptomes describe patient subtypes in systemic lupus erythematosus. PLoS ONE 10, e0141171 (2015
78. Banchereau R., et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 165, 551-565 (2016
79. Gaipl U. S., et al. Cooperation between C1q and DNase I in the clearance of necrotic cell-derived chromatin. Arthritis Rheum. 50, 640-649 (2004
80. Janko C., et al. CRP/anti-CRP antibodies assembly on the surfaces of cell remnants switches their phagocytic clearance toward inflammation. Front. Immunol. 2, 70 (2011
81. Wilber A., O?Connor T. P., Lu M. L., Karimi A., & Schneider M. C. Dnase1l3 deficiency in lupus-prone MRL and NZB/W F1 mice. Clin. Exp. Immunol. 134, 46-52 (2003
82. Al Mayouf S. M., et al. Loss of function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus. Nat. Genet. 43, 1186-1188 (2011
83. Belot A., et al. Protein kinase Cδ deficiency causes Mendelian systemic lupus erythematosus with B cell-defective apoptosis and hyperproliferation. Arthritis Rheum. 65, 2161-2171 (2013
84. Dieker J., et al. Enhanced activation of dendritic cells by autologous apoptotic microvesicles in MRL/lpr mice. Arthritis Res. Ther. 17, 103 (2015
85. Honda K., et al. Spatiotemporal regulation of MyD88-IRF 7 signalling for robust type I interferon induction. Nature 434, 1035-1040 (2005
86. Barton G. M., Kagan J. C., & Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat. Immunol. 7, 49-56 (2006
87. Savarese E., et al. Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum. 58, 1107-1115 (2008
88. Pawar R. D., et al. Inhibition of Toll-like receptor 7 (TLR 7) or TLR 7 plus TLR 9 attenuates glomerulonephritis and lung injury in experimental lupus. J. Am. Soc. Nephrol. 18, 1721-1731 (2007
89. Pawar R. D., et al. Toll-like receptor 7 modulates immune complex glomerulonephritis. J. Am. Soc. Nephrol. 17, 141-149 (2006
90. Subramanian S., et al. A TLR7 translocation accelerates systemic autoimmunity in murine lupus. Proc. Natl Acad. Sci. USA 103, 9970-9975 (2006
91. Ramirez-Ortiz Z. G., et al. The receptor TREML4 amplifies TLR7 mediated signaling during antiviral responses and autoimmunity. Nat. Immunol. 16, 495-504 (2015
92. Papadimitraki E. D., et al. Expansion of Toll-like receptor 9 expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum. 54, 3601-3611 (2006
93. Christensen S. R., et al. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J. Exp. Med. 202, 321-331 (2005
94. Fukui R., et al. Unc93B1 restricts systemic lethal inflammation by orchestrating Toll-like receptor 7 and 9 trafficking. Immunity 35, 69-81 (2011
95. Ishikawa H., & Barber G. N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455, 674-678 (2008
96. Schlee M., & Hartmann G. Discriminating self from non-self in nucleic acid sensing. Nat. Rev. Immunol. 16, 566-580 (2016
97. Molineros J. E., et al. Admixture mapping in lupus identifies multiple functional variants within IFIH1 associated with apoptosis inflammation and autoantibody production. PLoS Genet. 9, e1003222 2013
98. Hornung V., et al. AIM2 recognizes cytosolic dsDNA and forms a caspase 1 activating inflammasome with ASC. Nature 458, 514-518 (2009
99. Choubey D. Interferon-inducible Ifi200 family genes as modifiers of lupus susceptibility. Immunol. Lett. 147, 10-17 (2012
100. Crow Y. J., & Manel N. Aicardi-Goutières syndrome and the type I interferonopathies. Nat. Rev. Immunol. 15, 429-440 (2015
101. Cuadrado E., et al. Aicardi-Goutières syndrome harbours abundant systemic and brain-reactive autoantibodies. Ann. Rheum. Dis. 74, 1931-1939 (2015
102. Munroe M. E., et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann. Rheum. Dis. 75, 2014-2021 (2016
103. Lu R., et al. Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. J. Autoimmun. 74, 182-193 (2016
104. Weckerle C. E., et al. Large-scale analysis of tumor necrosis factor α levels in systemic lupus erythematosus. Arthritis Rheum. 64, 2947-2952 (2012
105. Yarilina A., Park-Min K. H., Antoniv T., Hu X., & Ivashkiv L. B. TNF activates an IRF1 dependent autocrine loop leading to sustained expression of chemokines and STAT1 dependent type I interferon-response genes. Nat. Immunol. 9, 378-387 (2008
106. Liu Z., & Davidson A. IFNα inducible models of murine SLE. Front. Immunol. 4, 306 (2013
107. Castellano G., et al. Local synthesis of interferon α in lupus nephritis is associated with type I interferons signature and LMP7 induction in renal tubular epithelial cells. Arthritis Res. Ther. 17, 72 (2015
108. Farkas L., Beiske K., Lund-Johansen F., Brandtzaeg P., & Jahnsen F. L. Plasmacytoid dendritic cells (natural interferon α/β producing cells) accumulate in cutaneous lupus erythematosus lesions. Am. J. Pathol. 159, 237-243 (2001
109. Fairhurst A. M., et al. Systemic IFN α drives kidney nephritis in B6.Sle123 mice. Eur. J. Immunol. 38, 1948-1960 (2008
110. Liu Z., et al. Interferon α accelerates murine systemic lupus erythematosus in a T cell-dependent manner. Arthritis Rheum. 63, 219-229 (2011
111. Rudloff I., et al. Brief report: interleukin 38 exerts antiinflammatory functions and is associated with disease activity in systemic lupus erythematosus. Arthritis Rheumatol. 67, 3219-3225 (2015
112. Wang D., Drenker M., Eiz-Vesper B., Werfel T., & Wittmann M. Evidence for a pathogenetic role of interleukin 18 in cutaneous lupus erythematosus. Arthritis Rheum. 58, 3205-3215 (2008
113. Talaat R. M., Mohamed S. F., Bassyouni I. H., & Raouf A. A. TH1/TH2/TH17/TReg cytokine imbalance in systemic lupus erythematosus (SLE) patients: correlation with disease activity. Cytokine 72, 146-153 (2015
114. Kyttaris V. C., Juang Y. T., Tenbrock K., Weinstein A., & Tsokos G. C. Cyclic adenosine 5′ monophosphate response element modulator is responsible for the decreased expression of c fos and activator protein 1 binding in T cells from patients with systemic lupus erythematosus. J. Immunol. 173, 3557-3563 (2004
115. Solomou E. E., Juang Y. T., Gourley M. F., Kammer G. M., & Tsokos G. C. Molecular basis of deficient IL 2 production in T cells from patients with systemic lupus erythematosus. J. Immunol. 166, 4216-4222 (2001
116. Kyttaris V. C., Kampagianni O., & Tsokos G. C. Treatment with anti-interleukin 23 antibody ameliorates disease in lupus-prone mice. Biomed. Res. Int. 2013, 861028 (2013
117. Pers J. O., et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann. NY Acad. Sci. 1050, 34-39 (2005
118. Stohl W., et al. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum. 52, 2080-2091 (2005
119. Liu Z., & Davidson A. BAFF and selection of autoreactive B cells. Trends Immunol. 32, 388-394 (2011
120. Carter L. M., Isenberg D. A., & Ehrenstein M. R. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum. 65, 2672-2679 (2013
121. Ledford H. After half-century?s wait approval paves path for new lupus drugs. Nat. Med. 17, 400 (2011
122. Furie R., et al. A phase III randomized placebo-controlled study of belimumab a monoclonal antibody that inhibits B lymphocyte stimulator in patients with systemic lupus erythematosus. Arthritis Rheum. 63, 3918-3930 2011
123. Navarra S. V., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised placebo-controlled phase 3 trial. Lancet 377, 721-731 (2011
124. Jin O., et al. Systemic lupus erythematosus patients have increased number of circulating plasmacytoid dendritic cells but decreased myeloid dendritic cells with deficient CD83 expression. Lupus 17, 654-662 (2008
125. Batteux F., Palmer P., Daeron M., Weill B., & Lebon P. FcγRII (CD32)-dependent induction of interferon α by serum from patients with lupus erythematosus. Eur. Cytokine Netw. 10, 509-514 (1999
126. Mozaffarian N., Wiedeman A. E., & Stevens A. M. Active systemic lupus erythematosus is associated with failure of antigen-presenting cells to express programmed death ligand 1. Rheumatology (Oxford) 47, 1335-1341 (2008
127. Leonard D., et al. Activated T cells enhance interferon α production by plasmacytoid dendritic cells stimulated with RNA-containing immune complexes. Ann. Rheum. Dis. 75, 1728-1734 (2015
128. Celhar T., et al. RNA sensing by conventional dendritic cells is central to the development of lupus nephritis. Proc. Natl Acad. Sci. USA 112, E6195-E6204 2015
129. Wu S. A., et al. Impaired phagocytosis and susceptibility to infection in pediatric-onset systemic lupus erythematosus. Lupus 22, 279-288 (2013
130. Bengtsson A. A., et al. Low production of reactive oxygen species in granulocytes is associated with organ damage in systemic lupus erythematosus. Arthritis Res. Ther. 16, R120 2014
131. De Ravin S. S., et al. Chronic granulomatous disease as a risk factor for autoimmune disease. J. Allergy Clin. Immunol. 122, 1097-1103 (2008
132. Magnani A., et al. Inflammatory manifestations in a single-center cohort of patients with chronic granulomatous disease. J. Allergy Clin. Immunol. 134, 655-662 (2014
133. Campbell A. M., Kashgarian M., & Shlomchik M. J. NADPH oxidase inhibits the pathogenesis of systemic lupus erythematosus. Sci. Transl Med. 4, 157ra141 (2012
134. Kelkka T., et al. Reactive oxygen species deficiency induces autoimmunity with type 1 interferon signature. Antioxid. Redox Signal. 21, 2231-2245 (2014
135. Lood C., et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat. Med. 22, 146-153 (2016
136. Sanford A. N., Suriano A. R., Herche D., Dietzmann K., & Sullivan K. E. Abnormal apoptosis in chronic granulomatous disease and autoantibody production characteristic of lupus. Rheumatology (Oxford) 45, 178-181 (2006
137. Villanueva E., et al. Netting neutrophils induce endothelial damage infiltrate tissues and expose immunostimulatory molecules in systemic lupus erythematosus. J. Immunol. 187, 538-552 (2011
138. Smith C. K., & Kaplan M. J. The role of neutrophils in the pathogenesis of systemic lupus erythematosus. Curr. Opin. Rheumatol. 27, 448-453 (2015
139. Garcia-Romo G. S., et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl Med. 3, 73ra20 (2011
140. Lande R., et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci. Transl Med. 3, 73ra19 (2011
141. O?Gorman W. E., et al. Single-cell systems-level analysis of human Toll-like receptor activation defines a chemokine signature in patients with systemic lupus erythematosus. J. Allergy Clin. Immunol. 136, 1326-1336 (2015
142. Hill G. S., et al. Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int. 59, 304-316 (2001
143. Asanuma Y., et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349, 2407-2415 (2003
144. Li J., Liu C. H., Xu D. L., & Gao B. Significance of CD163 positive macrophages in proliferative glomerulonephritis. Am. J. Med. Sci. 350, 387-392 (2015
145. Masek-Hammerman K., et al. Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus erythematosus. Clin. Exp. Immunol. 183, 258-270 (2016
146. Chen Y., Cuda C., & Morel L. Genetic determination of T cell help in loss of tolerance to nuclear antigens. J. Immunol. 174, 7692-7702 (2005
147. Chavele K. M., & Ehrenstein M. R. Regulatory T cells in systemic lupus erythematosus and rheumatoid arthritis. FEBS Lett. 585, 3603-3610 (2011
148. Juang Y. T., et al. Systemic lupus erythematosus serum IgG increases CREM binding to the IL 2 promoter and suppresses IL 2 production through CaMKIV. J. Clin. Invest. 115, 996-1005 (2005
149. Enyedy E. J., et al. Fc ϵ receptor type I γ chain replaces the deficient T cell receptor ζ chain in T cells of patients with systemic lupus erythematosus. Arthritis Rheum. 44, 1114-1121 (2001
150. Liossis S. N., Ding X. Z., Dennis G. J., & Tsokos G. C. Altered pattern of TCR/CD3 mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor ζ chain. J. Clin. Invest. 101, 1448-1457 (1998
151. Fernandez D. R., et al. Activation of mammalian target of rapamycin controls the loss of TCRζ in lupus T cells through HRES 1/Rab4 regulated lysosomal degradation. J. Immunol. 182, 2063-2073 (2009
152. Crispin J. C., et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL 17 and infiltrate the kidneys. J. Immunol. 181, 8761-8766 (2008
153. Liu Y., et al. Increased expression of TLR2 in CD4+ T cells from SLE patients enhances immune reactivity and promotes IL 17 expression through histone modifications. Eur. J. Immunol. 45, 2683-2693 (2015
154. Apostolidis S. A., Crispin J. C., & Tsokos G. C. IL 17 producing T cells in lupus nephritis. Lupus 20, 120-124 (2011
155. Crispin J. C., & Tsokos G. C. Human TCR αβ+ CD4- CD8- T cells can derive from CD8+ T cells and display an inflammatory effector phenotype. J. Immunol. 183, 4675-4681 (2009
156. Shivakumar S., Tsokos G. C., & Datta S. K. T cell receptor α/β expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J. Immunol. 143, 103-112 1989
157. Mandik-Nayak L., et al. MRL-lpr/lpr mice exhibit a defect in maintaining developmental arrest and follicular exclusion of anti-double-stranded DNA B cells. J. Exp. Med. 189, 1799-1814 (1999
158. Sinai P., et al. T/B cell interactions are more transient in response to weak stimuli in SLE-prone mice. Eur. J. Immunol. 44, 3522-3531 (2014
159. Mietzner B., et al. Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors. Proc. Natl Acad. Sci. USA 105, 9727-9732 (2008
160. Keszei M., et al. Expansion of an osteopontin-expressing T follicular helper cell subset correlates with autoimmunity in B6.Sle1b mice and is suppressed by the H1 isoform of the Slamf6 receptor. FASEB J. 27, 3123-3131 (2013
161. Yang X., et al T follicular helper cells mediate expansion of regulatory B cells via IL 21 in lupus-prone MRL/lpr mice. PLoS ONE 8, e62855 2013
162. Choi J. Y., et al. Circulating follicular helper-like T cells in systemic lupus erythematosus: association with disease activity. Arthritis Rheumatol. 67, 988-999 (2015
163. Szabo K., Papp G., Szanto A., Tarr T., & Zeher M. A comprehensive investigation on the distribution of circulating follicular T helper cells and B cell subsets in primary Sjögren?s syndrome and systemic lupus erythematosus. Clin. Exp. Immunol. (2015
164. Le Coz C., et al. Circulating TFH subset distribution is strongly affected in lupus patients with an active disease. PLoS ONE 8, e75319 (2013
165. Liarski V. M., et al. Cell distance mapping identifies functional T follicular helper cells in inflamed human renal tissue. Sci. Transl Med. 6, 230ra46 (2014
166. Simpson N., et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum. 62, 234-244 (2010
167. Jacquemin C., et al. OX40 ligand contributes to human lupus pathogenesis by promoting T follicular helper response. Immunity 42, 1159-1170 (2015
168. von Spee-Mayer C., et al. Low-dose interleukin 2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann. Rheum. Dis. (2015
169. Dörner T., Jacobi A. M., Lee J., & Lipsky P. E. Abnormalities of B cell subsets in patients with systemic lupus erythematosus. J. Immunol. Methods 363, 187-197 (2011
170. Guerrier T., Youinou P., Pers J. O., & Jamin C. TLR9 drives the development of transitional B cells towards the marginal zone pathway and promotes autoimmunity. J. Autoimmun. 39, 173-179 (2012
171. Thien M., et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20, 785-798 (2004
172. Lesley R., et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 20, 441-453 (2004
173. Mackay F., et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 190, 1697-1710 (1999
174. Arbuckle M. R., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349, 1526-1533 (2003
175. Wardemann H., et al. Predominant autoantibody production by early human B cell precursors. Science 301, 1374-1377 (2003
176. Odendahl M., et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J. Immunol. 165, 5970-5979 (2000
177. Gao N., et al. Impaired suppressive capacity of activation-induced regulatory B cells in systemic lupus erythematosus. Arthritis Rheumatol. 66, 2849-2861 (2014
178. Pillai S., Mattoo H., & Cariappa A. B cells and autoimmunity. Curr. Opin. Immunol. 23, 721-731 (2011
179. Koscec M., et al. Autoantibodies to ribosomal P proteins penetrate into live hepatocytes and cause cellular dysfunction in culture. J. Immunol. 159, 2033-2041 (1997
180. Hung T., et al. The Ro60 autoantigen binds endogenous retroelements and regulates inflammatory gene expression. Science 350, 455-459 (2015
181. Kaur K., et al. High affinity antibodies against influenza characterize the plasmablast response in SLE patients after vaccination. PLoS ONE 10, e0125618 2015
182. Dema B., et al. Autoreactive IgE is prevalent in systemic lupus erythematosus and is associated with increased disease activity and nephritis. PLoS ONE 9, e90424 2014
183. Henault J., et al. Self-reactive IgE exacerbates interferon responses associated with autoimmunity. Nat. Immunol. 17, 196-203 (2016
184. Liphaus B. L., Jesus A. A., Silva C. A., Coutinho A., & Carneiro-Sampaio M. Increased IgE serum levels are unrelated to allergic and parasitic diseases in patients with juvenile systemic lupus erythematosus. Clinics (São Paulo) 67, 1275-1280 (2012
185. Charles N., Hardwick D., Daugas E., Illei G. G., & Rivera J. Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nat. Med. 16, 701-707 (2010
186. Charles N., et al. Lyn kinase controls basophil GATA 3 transcription factor expression and induction of TH2 cell differentiation. Immunity 30, 533-543 (2009
187. Dema B., et al. Immunoglobulin E plays an immunoregulatory role in lupus. J. Exp. Med. 211, 2159-2168 (2014
188. Ge Y., et al. Cgnz1 allele confers kidney resistance to damage preventing progression of immune complex-mediated acute lupus glomerulonephritis. J. Exp. Med. 210, 2387-2401 (2013
189. Watkins A. A., et al. IRF5 deficiency ameliorates lupus but promotes atherosclerosis and metabolic dysfunction in a mouse model of lupus-associated atherosclerosis. J. Immunol. 194, 1467-1479 (2015
190. Cervera R., et al. Morbidity and mortality in systemic lupus erythematosus during a 5 year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 78, 167-175 (1999
191. Flower C., Hennis A., Hambleton I. R., & Nicholson G. Lupus nephritis in an Afro-Caribbean population: renal indices and clinical outcomes. Lupus 15, 689-694 (2006
192. Chung S. A., et al. Lupus nephritis susceptibility loci in women with systemic lupus erythematosus. J. Am. Soc. Nephrol. 25, 2859-2870 (2014
193. Matsuda M., et al. Gene expression of PDGF and PDGF receptor in various forms of glomerulonephritis. Am. J. Nephrol. 17, 25-31 (1997
194. Ostendorf T., et al. Antagonism of PDGF D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis. J. Am. Soc. Nephrol. 17, 1054-1062 (2006
195. Ichii O., et al. Decreased miR 26a expression correlates with the progression of podocyte injury in autoimmune glomerulonephritis. PLoS ONE 9, e110383 2014
196. Flur K., et al. Viral RNA induces type I interferon-dependent cytokine release and cell death in mesangial cells via melanoma-differentiation-associated gene 5: implications for viral infection-associated glomerulonephritis. Am. J. Pathol. 175, 2014-2022 (2009
197. Ichinose K., et al. Cutting edge: calcium/calmodulin-dependent protein kinase type IV is essential for mesangial cell proliferation and lupus nephritis. J. Immunol. 187, 5500-5504 (2011
198. Ichinose K., et al. Lupus nephritis IgG induction of calcium/calmodulin-dependent kinase type IV expression in podocytes and alteration of their function. Arthritis Rheumatol. 68, 944-952 (2016
199. Ichinose K., Juang Y. T., Crispin J. C., Kis-Toth K., & Tsokos G. C. Suppression of autoimmunity and organ pathology in lupus-prone mice upon inhibition of calcium/calmodulin-dependent protein kinase type IV. Arthritis Rheum. 63, 523-529 (2011
200. Tshilela K. A., et al. Glomerular cytokine expression in murine lupus nephritis. Clin. Exp. Nephrol. 20, 23-29 (2016
201. Espinosa A., et al. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL 23-TH17 pathway. J. Exp. Med. 206, 1661-1671 (2009
202. Oke V., et al. High Ro52 expression in spontaneous and UV induced cutaneous inflammation. J. Invest. Dermatol. 129, 2000-2010 (2009
203. Fabini G., Rutjes S. A., Zimmermann C., Pruijn G. J., & Steiner G. Analysis of the molecular composition of Ro ribonucleoprotein complexes: identification of novel Y RNA-binding proteins. Eur. J. Biochem. 267, 2778-2789 (2000
204. Ho R. C., et al. Genetic variants that are associated with neuropsychiatric systemic lupus erythematosus. J. Rheumatol. 43, 541-551 (2016
205. Namjou B., et al. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun. 12, 270-279 (2011
206. Jacob A., et al. Inhibition of C5a receptor alleviates experimental CNS lupus. J. Neuroimmunol. 221, 46-52 (2010
207. Jacob A., et al. C5a alters blood-brain barrier integrity in experimental lupus. FASEB J. 24, 1682-1688 2010
208. Ho R. C., et al. A meta-analysis of serum and cerebrospinal fluid autoantibodies in neuropsychiatric systemic lupus erythematosus. Autoimmun. Rev. 15, 124-138 (2016
209. Wen J., et al. Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway. J. Autoimmun. 43, 44-54 (2013
210. Pondman K. W., Stoop J. W., Cormane R. H., & Hannema A. J. Abnormal C1 in a patient with systemic lupus erythematosus. J. Immunol. 101, 811 (1968
211. Kallel-Sellami M., et al. Pediatric systemic lupus erythematosus with C1q deficiency. Ann. NY Acad. Sci. 1108, 193-196 (2007
212. Wu Y. L., Brookshire B. P., Verani R. R., Arnett F. C., & Yu C. Y. Clinical presentations and molecular basis of complement C1r deficiency in a male African-American patient with systemic lupus erythematosus. Lupus 20, 1126-1134 (2011
213. Suzuki Y., Ogura Y., Otsubo O., Akagi K., & Fujita T. Selective deficiency of C1s associated with a systemic lupus erythematosus-like syndrome. Report of a case. Arthritis Rheum. 35, 576-579 (1992
214. Kemp M. E., Atkinson J. P., Skanes V. M., Levine R. P., & Chaplin D. D. Deletion of C4A genes in patients with systemic lupus erythematosus. Arthritis Rheum. 30, 1015-1022 (1987
215. Wahl R., et al. C2 deficiency and a lupus erythematosus-like illness: family re evaluation. Ann. Intern. Med. 90, 717-718 (1979
216. Pussell B. A., Bourke E., Nayef M., Morris S., & Peters D. K. Complement deficiency and nephritis: a report of a family. Lancet 1, 675-677 (1980
217. Battersby A. C., Cale A. M., Goldblatt D., & Gennery A. R. Clinical manifestations of disease in X linked carriers of chronic granulomatous disease. J. Clin. Immunol. 33, 1276-1284 (2013
218. Klar A., et al. Prolidase deficiency: it looks like systemic lupus erythematosus but it is not. Eur. J. Pediatr. 169, 727-732 (2010
219. Urushihara M., et al. Sisters with α mannosidosis and systemic lupus erythematosus. Eur. J. Pediatr. 163, 192-195 (2004
220. Lee-Kirsch M. A., et al. Familial chilblain lupus a monogenic form of cutaneous lupus erythematosus maps to chromosome 3p. Am. J. Hum. Genet. 79, 731-737 (2006
221. Rice G., et al. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi- Goutières syndrome. Am. J. Hum. Genet. 80, 811-815 (2007
222. Yasutomo K., et al. Mutation of DNASE1 in people with systemic lupus erythematosus. Nat. Genet. 28, 313-314 (2001
223. Ramantani G., et al. Aicardi-Goutières syndrome and systemic lupus erythematosus (SLE) in a 12 year-old boy with SAMHD1 mutations. J. Child Neurol. 26, 1425-1428 (2011
224. Briggs T. A., et al. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat. Genet. 43, 127-131 (2011
225. Crow Y. J., et al. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR and IFIH1. Am. J. Med. Genet. A 167A, 296-312 (2015
226. Rice G. I., et al. Mutations in ADAR1 cause Aicardi- Goutières syndrome associated with a type I interferon signature. Nat. Genet. 44, 1243-1248 (2012
227. Jang M. A., et al. Mutations in DDX58, which encodes RIG I, cause atypical Singleton-Merten syndrome. Am. J. Hum. Genet. 96, 266-274 (2015
228. Liu Y., et al. Activated STING in a vascular and pulmonary syndrome. N. Engl. J. Med. 371, 507-518 (2014
229. Zhang X., et al. Human intracellular ISG15 prevents interferon α/β over-amplification and auto-inflammation. Nature 517, 89-93 (2015
230. Brehm A., et al. Additive loss of function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. J. Clin. Invest. 125, 4196-4211 (2015
231. Wu J., et al. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J. Clin. Invest. 98, 1107-1113 (1996
232. Xiang N., Li X. M., Wang G. S., Tao J. H., & Li X. P. Association of FAS gene polymorphisms with systemic lupus erythematosus: a meta-analysis. Mol. Biol. Rep. 40, 407-415 (2013
233. Rieux-Laucat F., et al. Mutations in FAS associated with human lymphoproliferative syndrome and autoimmunity. Science 268, 1347-1349 (1995
234. Bader-Meunier B., et al. Are RASopathies new monogenic predisposing conditions to the development of systemic lupus erythematosus? Case report and systematic review of the literature. Semin. Arthritis Rheum. 43, 217-219 (2013
235. Chen K., et al. Autoimmunity due to RAG deficiency and estimated disease incidence in RAG1/2 mutations. J. Allergy Clin. Immunol. 133, 880-882. e810 (2014
236. Walter J. E., et al. Impaired receptor editing and heterozygous RAG2 mutation in a patient with systemic lupus erythematosus and erosive arthritis. J. Allergy Clin. Immunol. 135, 272-273 (2014